Acted Therapeutics raises £5 million for cancer cachexia


Actimed Therapeutics Ltd, a UK-based clinical-stage specialty pharmaceutical company focused on bringing innovation to the treatment of cancer cachexia and other muscle wasting disorders, has raised more than £5 million ($6.4 million) in an oversubscribed Series A financing round. .

This investment will support the development of Actimed’s pipeline, including S-pindolol benzoate, with ongoing preparations for a phase 2b/3 program (IMPACT program) targeted at the treatment of cancer cachexia in non-small cell lung cancer and colorectal cancer.

The Series A round saw participation from existing investors, including India-based pharmaceutical company Mankind Pharma, as well as new non-institutional investors.

Proceeds from the financing will be used to further advance Actimed’s development portfolio, particularly its main asset S-pindolol benzoate. Actimed is currently finalizing the preparation of a regulatory filing for S-pindolol benzoate to support the initiation of the global IMPACT phase 2b/3 clinical development program.

S-pindolol has shown promising results in phase 2a, proof-of-concept trials, ACT-ONE trials, and the company has completed a pharmacokinetic/pharmacodynamic (PK/PD) study with S-pindolol benzoate that met all of the clinical standards defined previously. objective.

Earlier this year, Actimed launched a Series B financing round aimed at funding the IMPACT program through to completion. Series B financing is targeted to be completed in the second half of 2023.

Robin Bhattacherjee, chief executive officer of Actimed Therapeutics, said: “We are delighted to announce the swift and successful closing of our oversubscribed Series A financing round, which follows the £10 million seed financing we announced earlier this year. We are well positioned to advance the clinical development of S-pindolol benzoate, which has shown a very promising profile for the treatment of cancer cachexia, where there is still an unmet need.

“As we move into late-stage development, we are excited about the prospect of this important new therapy that has the potential to change the lives of patients suffering from this often fatal condition.”


Source link

Related Articles

Back to top button